Deleted Journal, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 28, 2024
Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(3), P. 702 - 702
Published: Jan. 22, 2025
The complement system includes soluble and cell surface proteins is an important arm of the innate immune system. Once activated, rapidly generates with inflammatory vasoactive activities. Although crucial to host defense homeostasis, its inappropriate or uncontrolled activation can also drive tissue injury. Glomerulopathy encompasses a spectrum diseases diverse etiologies, clinical presentations, outcomes. Among intricate web factors contributing glomerulopathies pathogenesis, role has emerged as focal point research interest therapeutic intervention. pioneer drug was eculizumab, which made it possible drastically change prognosis atypical hemolytic uremic syndrome, otherwise fatal disease. This comprehensive review aims elucidate multifaceted interplay between pathways glomerulopathies, shedding light on potential for targeted therapies improved patient care.
Language: Английский
Citations
1
Seminars in Nephrology, Journal Year: 2025, Volume and Issue: unknown, P. 151573 - 151573
Published: March 1, 2025
Language: Английский
Citations
0
Canadian Journal of Kidney Health and Disease, Journal Year: 2025, Volume and Issue: 12
Published: Jan. 1, 2025
Purpose of the review: Immunoglobulin A (IgA) nephropathy (IgAN) is most common primary glomerular kidney disease. Children and adults are presumed to have same disease treated similarly. However, there differences between childhood IgAN adult that may require unique treatment considerations, even after transition nephrology services. narrative review was conducted compare describe distinct characteristics IgAN. Reframing can inform guideline recommendations IgAN, development targeted therapies, clinical trial design. Sources information: Medline Embase were searched for reports on children with published January 2013 December 2023 (updated May 2024). The search not restricted by age group, outcomes reported, language, or study Randomized controlled trials (RCTs), observational studies, articles, conference abstracts included. total 3104 retrieved. Forty-seven (37 studies 10 reviews) included in review. Two RCTs 35 a 45 085 participants (9223 862 adults). Method: Data extracted IgA vasculitis–associated nephritis. Findings described no statistical comparisons due variations interventions outcome definitions. Key findings: Gross hematuria obvious difference (60-88% vs 15-20%). Nephrotic syndrome more children, approaching up 44%, while <18% had nephrotic syndrome. biopsied sooner (6 15 months) inflammatory lesions (mesangial hypercellularity: 41-82% 38-64%; endocapillary 39-58% 17-34%). Chronic prevalent (segmental sclerosis: 62-77% 8-51%; interstitial fibrosis/tubular atrophy: 34-37% 1-18%). use immunosuppressive therapy higher (46-84% 35-56%). started than adults. Adults likely be optimized renin-angiotensin system inhibitors (87-94% 49-75%). better function at diagnosis (estimated filtration rate 90-128 50-88 ml/min/1.73 m 2 ), also survival, failure 3.1% 13.4% 5 years. risk alleles levels mannose-binding lectin Limitations: Most retrospective observational, limited data mechanisms. pooled analysis because important definitions measurements baseline outcomes. from countries established urine screening programs different compared without programs. Some observed practice variation delayed (lead-time bias). Well-designed prospective standardized measures assessment reduce heterogeneity improve results reviews. Conclusion: Inherent Approaching as separate condition could lead discovery therapies management during care.
Language: Английский
Citations
0
World Journal of Clinical Cases, Journal Year: 2025, Volume and Issue: 13(19)
Published: March 18, 2025
Immunoglobulin (Ig) A nephropathy is the most common type of primary glomerulonephritis globally. It typically manifests with microscopic hematuria and a spectrum proteinuria, although rapidly progressive may occur in rare instances. Deposition IgA mesangium seems to be underlying disease mechanism. Despite current treatment, progress into end-stage renal disease, indicating necessity for development new therapeutic agents. Lifestyle modifications anti-proteinuric treatment are recommended, steroids have shown beneficial high risk groups. Nevertheless, other conventional immunosuppressive agents, such as cyclophosphamide mycophenolate mofetil, considered, despite lack sufficient evidence support their efficacy. considerable proportion cases remain unresponsive these treatments, underscoring need novel approaches. There several promising drugs, B-cell lineage depleting agents or complement system inhibitors, that currently undergoing clinical trials. These therapies considered use selected cases.
Language: Английский
Citations
0
Kidney International Reports, Journal Year: 2025, Volume and Issue: unknown
Published: April 1, 2025
Language: Английский
Citations
0
Medicina, Journal Year: 2025, Volume and Issue: 61(5), P. 807 - 807
Published: April 26, 2025
Background & Objectives: Targeted-release budesonide (TRB) is the first approved agent aimed at targeting early pathogenetic cascade in IgA nephropathy (IgAN). Materials and Methods: This prospective study included Caucasian IgAN patients diagnosed within last 5 years, who had started a 10-month TRB treatment were followed outpatient clinic. All participants been on maximal supportive care dose for least previous 6 months. Kidney function proteinuria levels recorded start of (T0) 3, 6, 10 months (T3, T6, T10, respectively), while urinary monocyte chemotactic protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9) clusterin (CLU) measured T0 T3. Results: In cohort all (mean age 53.24 ± 12.76 estimated glomerular filtration rate (eGFR 52.84 25.93 mL/min/1.73 m2, 2.84 1.26 g/24 h), significant correlations observed between MMP-9 MCP-1 (r = 0.74, p 0.004), uCLU 0.77, 0.002), 0.65, 0.01). At T3, correlation CLU (uCLU) persisted 0.71, 0.03). Higher −0.560, 0.046) −0.330, 0.012) associated with reduced proteinuria. Conversely, increased T3 0.599, 0.031) was worsening Conclusions: The response to heterogeneous, recent diagnosis (RD) showing improved kidney proteinuria, older (OD) exhibited biomarkers declining function. Therefore, interventions are crucial patients. Finally, studied can be used prognostically monitor disease progression.
Language: Английский
Citations
0
Journal of Nephrology, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 20, 2024
Language: Английский
Citations
0
Deleted Journal, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 28, 2024
Citations
0